| 1. |
- Andreasson, Ulf, 1968, et al.
(författare)
-
Method and Clinical Validation of Biomarkers for Neurodegenerative Diseases
- 2021
-
Ingår i: Cerebrospinal Fluid Biomarkers. Neuromethods, vol 168. Teunissen C.E., Zetterberg H. (eds). - New York, NY : Springer. - 0893-2336. - 9781071613184 ; , s. 163-173
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- In the Merriam-Webster dictionary, one definition of the word valid is “well-grounded or justifiable: being at once relevant and meaningful.” Validation is then the process of determining the degree of validity. From this broad definition, it follows that validations can be made in many different fields with quite different implications. When talking about validation, it is therefore important to specify the subject under scrutiny and in this chapter the focus will be on validation of biomarkers. © 2021, Springer Science+Business Media, LLC, part of Springer Nature.
|
|
| 2. |
- Blennow, Kaj, 1958, et al.
(författare)
-
Fluid Biomarkers in Alzheimer Disease, 91
- 2012
-
Ingår i: The biology of Alzheimer disease / edited by Dennis J. Selkoe, David M. Holtzman, and Eckhard Mandelkow.. - Cold Spring Harbor, N.Y. : Cold Spring Harbor Laboratory Press. - 9781936113446 ; , s. 91-114
-
Bokkapitel (refereegranskat)
|
|
| 3. |
- Blennow, Kaj, 1958, et al.
(författare)
-
Likvoranalyser : Del av: Sjukdomar i centrala nervsystemet
- 2012
-
Ingår i: Laurells Klinisk kemi i praktisk medicin 9., [rev. och utök.] uppl. /redaktion: Peter Nilsson-Ehle, Maria Berggren Söderlund, Elvar Theodorsson ; redaktionskommitté: Charlotte Becker, Kjell Grankvist, Anders Grubb, Göran Lindstedt, Per Simonsson. - LUND : Studentlitteratur. - 9789144047874
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)
|
|
| 4. |
- Bolouri, Hayde, 1957, et al.
(författare)
-
ANIMAL MODELS FOR CONCUSSION: MOLECULAR AND COGNITIVE ASSESSMENTS - RELEVANCE TO SPORT AND MILITARY CONCUSSIONS
- 2014
-
Ingår i: Brain Neurotrauma: Molecular, Neuropsychological and Rehabilitation. Firas H. Kobeissy (Ed.). - USA : Taylor & Francis. - 9781466565982 ; , s. 643-656
-
Bokkapitel (refereegranskat)abstract
- Abstract Mild traumatic brain injury (mTBI) or concussion, the most common form of brain injury, results in a complex cascade of injurious and reparative events in the brain and is not always as mild in nature as the mTBI term would imply. Over the last decades it has become clear that repeated mTBIs may give rise to chronic and sometimes progressive brain changes that may lead to a broad range of psychiatric and neurological symptoms. Presently, there is a convention to categorize TBI into three groups: mild, moderate, and severe, based on initial presentation. At the more severe end of the injury spectrum, the correlation between initial injury severity rating and various outcome measures is relatively robust. At the milder end of the spectrum, this correlation is less tight, and over the last 100 years this has generated confusion with regards to the typical presentation and outcome of milder injuries. For a successful translation of basic science knowledge to the clinic to occur, further techniques and models are needed that better reflect mTBI in humans. The purpose of this chapter is to overview the underlying evidence for the necessity of animal models for mTBI in sports and other high risk activities such as military service.
|
|
| 5. |
- Brinkmalm, Ann, et al.
(författare)
-
Detection of α-Synuclein in Biological Samples Using Mass Spectrometry
- 2019
-
Ingår i: Methods in molecular biology (Clifton, N.J.). - New York, NY : Springer. - 1940-6029. ; , s. 209-220
-
Bokkapitel (refereegranskat)abstract
- Here we describe a method using mass spectrometry to characterize and quantify immuno-enriched α-synuclein forms from biochemically fractionated brain tissue.
|
|
| 6. |
- Fumagalli, G., et al.
(författare)
-
Assessment of Neurofilament Light Protein as a Serum Biomarker in Rodent Models of Toxic-Induced Peripheral Neuropathy
- 2021
-
Ingår i: Experimental Neurotoxicology Methods. Llorens J., Barenys M. (eds). - New York, NY : Springer. - 0893-2336. - 9781071616376 ; , s. 267-275
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- Chemotherapy-Induced Peripheral Neurotoxicity (CIPN) is a side effect frequently caused by common antitumor drugs, which may induce a severe and persistent limitation of the quality of life of cancer patients. Today, nerve conduction studies are considered the most objective indicators for CIPN diagnosis. Unfortunately, they are not easily available at most oncology centers. Therefore, a noninvasive and highly sensitive method is required to confirm nerve damage. Increased evidence supports the potential utility of fluid-based biomarkers to predict tissue damage and to monitor neurotoxicity due to drug administration or the efficacy of disease-modifying treatments. Neurofilaments, the major intermediate filaments in neurons that are specifically expressed in axons, have been investigated as potential biomarker candidates that might be used for this purpose. Neurofilament light chain (NfL) protein is increasingly proposed as a blood biomarker in several neurological diseases mainly affecting the central nervous system. In addition, analysis of serum NfL was evaluated also in peripheral neuropathies including Guillain–Barré syndrome, chronic inflammatory demyelinating and vasculitic neuropathies, and Charcot–Marie–Tooth. This chapter aims to provide an overview of the methods that allow NfL quantification in serum, focusing on the most recent ultrasensitive single molecule array (Simoa) assay. This technique is likely to be the best method for NfL dosage in CIPN models to predict the onset of large caliber neuronal dysfunction. Since blood sampling is an easily accessible technique, serum NfL may provide important help to monitor neuroaxonal damage after chemotherapy treatment, and might represent promising tools to follow CIPN progress. © 2021, Springer Science+Business Media, LLC, part of Springer Nature.
|
|
| 7. |
- Hanrieder, Jörg, 1980, et al.
(författare)
-
MALDI imaging mass spectrometry: Neurochemical imaging of proteins and peptides
- 2019
-
Ingår i: Neuroproteomics. Ka Wan Li (red.). - New York, NY : Springer. - 0893-2336 .- 1940-6045. - 9781493996612 ; , s. 179-197
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- © Springer Science+Business Media, LLC, part of Springer Nature 2019. The central nervous system (CNS) constitutes the most intricate tissue in the human body. Neurological diseases, in particular, have a complex pathophysiology and are heterogeneous in their pathological and clinical presentation and therefore poorly understood on a molecular level. Increased insight in molecular CNS disease pathophysiology relates directly to the advancement of novel bioanalytical technologies that allow highly resolved, sensitive, specific, and comprehensive molecular analysis and molecular imaging in complex biological tissues, and in the CNS in particular. Imaging mass spectrometry (IMS) is an emerging technique for molecular imaging, characterized by its high molecular specificity and is therefore a powerful approach for investigating molecular localization patterns in CNS-derived tissue and cells. Over the last 20 years, IMS has been demonstrated to be a promising technology for chemical imaging in biochemical studies, but its application in clinical research is still in its infancy. The goal of this chapter is to provide the reader with a detailed step-by-step guide through the IMS workflow for the successful replication of published experimental data. Moreover, the aim is to give a concise overview of the major developments and applications of matrix-assisted laser desorption ionization (MALDI) based imaging mass spectrometry for neurochemical profiling with particular focus on protein and peptide imaging in neurodegenerative disease pathology.
|
|
| 8. |
- Heslegrave, A. J., et al.
(författare)
-
A Selected reaction monitoring protocol for the measurement of sTREM2 in cerebrospinal fluid
- 2018
-
Ingår i: Biomarkers for Preclinical Alzheimer’s Disease. Perneczky R. (red.). - New York, NY : Springer. - 0893-2336. - 9781493976744 ; , s. 169-177
-
Bokkapitel (refereegranskat)abstract
- Mass spectrometry plays an increasingly important role in the biomarker field with the advent of targeted proteomics. Tryptic peptides from a protein of interest can be used to create a targeted assay to interrogate cerebrospinal fluid (CSF) for biomarkers. Since heterozygous mutations in the TREM2 gene have been associated with an increased risk of Alzheimer’s disease, measuring this soluble protein in CSF has become a priority. This chapter demonstrates the development, optimization, and validation of a method to measure soluble TREM2 using a single reaction monitoring (SRM) targeted mass spectrometry assay. © 2018, Springer Science+Business Media, LLC.
|
|
| 9. |
- Lista, S, et al.
(författare)
-
Blood and cerebrospinal fluid biomarkers for Alzheimer’s disease
- 2017
-
Ingår i: Dementia. David Ames, John T. O'Brien, Alistair Burns (red.). - Boca Raton : CRC Press. - 9781498703116 ; , s. 528-538
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- In general, a biomarker denes a biological process or disease characteristic that is objectively measured (Biomarkers Denitions Working Group, 2001). Such measurements may be used for diagnostic purposes, but also to study physiological or pathophysiological mechanisms and to evaluate desired pharmacodynamic eects or side eects of pharmacological treatments. According to Biomarkers Denitions Working Group: ‘Molecular and Biochemical Markers of Alzheimer’s Disease’, the ideal biomarker for Alzheimer’s disease (AD) should detect a fundamental feature of neuropathology and be validated in neuropathologically con-rmed cases as well as have a diagnostic accuracy of at least 80% (e Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and National Institute on Aging Working Group, 1998). With respect to clinically relevant questions, such as detection, diagnosis, prediction and treatment of a given disease, biomarkers may serve certain distinct functions
|
|
| 10. |
- Luchsinger, J. A., et al.
(författare)
-
Tracking the potential involvement of metabolic disease in Alzheimer's disease—Biomarkers and beyond
- 2020
-
Ingår i: International Review of Neurobiology. Vol. 154. - : Elsevier. - 0074-7742. - 9780128200766 ; , s. 51-77
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- There is a vast literature linking systemic metabolic conditions to dementia due to Alzheimer's disease (AD). Advances in in vivo measurements of AD neuropathology using brain imaging, cerebrospinal fluid (CSF), and/or blood biomarkers have led to research in AD that uses in vivo biomarkers as outcomes, focusing primarily on amyloid, tau, and neurodegeneration as constructs. Studies of Type 2 Diabetes Mellitus (T2DM) and AD biomarkers seem to show that T2DM is not related to amyloid deposition, but is related to neurodegeneration and tau deposition. There is a dearth of studies examining adiposity, insulin resistance, and metabolic syndrome in relation to AD biomarkers and the associations in these studies are inconsistent. Metabolomics studies have reported associations of unsaturated fatty acids with AD neuropathology at autopsy, and sphingolipids and glycerophospholipids in relation to neurodegeneration and amyloid and tau. There are other neurodegenerative diseases, such as Lewy body disease that may overlap with AD, and specific biomarkers for these pathologies are being developed and should be integrated into AD biomarker research. More longitudinal studies are needed with concurrent assessment of metabolic factors and AD biomarkers in order to improve the opportunity to assess causality. Ideally, AD biomarkers should be integrated into clinical trials of interventions that affect metabolic factors. Advances in blood-based AD biomarkers, which are less costly and invasive compared with CSF and brain imaging biomarkers, could facilitate widespread implementation of AD biomarkers in studies examining the metabolic contribution to AD. © 2020 Elsevier Inc.
|
|
